Back to discover

Protein / target

Kelch-like ECH-associated protein 1

Encoded byKEAP1Q14145Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
3
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Ubiquitin-like ligase-substrate adaptor

Strongest disease association

Multiple Sclerosis

Via encoding gene KEAP1 · Genetic evidence · score 0.25

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

10 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination.

View complete UniProt function annotation

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination (PubMed:14585973, PubMed:15379550, PubMed:15572695, PubMed:15601839, PubMed:15983046, PubMed:37339955). KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes (PubMed:15601839, PubMed:16006525). In response to oxidative stress, different electrophile metabolites trigger non-enzymatic covalent modifications of highly reactive cysteine residues in KEAP1, leading to inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II detoxifying enzymes (PubMed:16006525, PubMed:17127771, PubMed:18251510, PubMed:19489739, PubMed:29590092). In response to selective autophagy, KEAP1 is sequestered in inclusion bodies following its interaction with SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and activation of NFE2L2/NRF2 (PubMed:20452972). The BCR(KEAP1) complex also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 sequestering activity and degradation (PubMed:28380357). The BCR(KEAP1) complex also targets BPTF and PGAM5 for ubiquitination and degradation by the proteasome (PubMed:15379550, PubMed:17046835)

Subcellular location

CytoplasmNucleus
Domains and Gene Ontology detail (23)

Domains & features

BTBBACK

Gene Ontology

  • Cactin filament
  • CCul3-RING ubiquitin ligase complex
  • Ccytoplasm
  • Ccytosol
  • Cendoplasmic reticulum
  • Cinclusion body
  • Cmidbody
  • Cnucleoplasm
  • Fdisordered domain specific binding
  • Fidentical protein binding
  • FRNA polymerase II-specific DNA-binding transcription factor binding
  • Ftranscription regulator inhibitor activity

624 aa · 70 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that reg…
  • ·RNA polymerase II-specific DNA-binding transcription factor binding
  • ·transcription regulator inhibitor activity
  • ·negative regulation of transcription by RNA polymerase II
View underlying pathways (6)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

CUL3RBX1SQSTM1NFE2L2NEIL2PGAM5IKBKBPALB2PTMADPP3KEAP1

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Immune System Diseases1 medicine
Multiple Sclerosis1 medicine
Multiple Sclerosis, Relapsing-Remitting1 medicine
Psoriasis1 medicine

3 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

dimethyl fumarate
Narrow target profileApprovedInhibitor

Kelch-like ECH-associated protein 1 inhibitor

Indicated for Immune System Diseases, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Psoriasis

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene KEAP1

Gene-level evidence surfaced through the gene KEAP1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Multiple Sclerosis
0.81Well supported

Clinical evidence dominant · Open Targets 0.64

Multiple Sclerosis, Relapsing-Remitting
0.69Moderately supported

Clinical evidence dominant · Open Targets 0.56

Psoriasis
0.59Moderately supported

Clinical evidence dominant · Open Targets 0.48

Immune System Diseases
0.57Moderately supported

Clinical evidence dominant · Open Targets 0.46

Adenocarcinoma of Lung
0.56Moderately supported

Somatic mutation evidence dominant · Open Targets 0.61

View evidence synthesis (5)
Multiple SclerosisWell supported
0.81
agreement 0.700.91
Clinical74%Genetic25%Literature1%

Open Targets aggregate 0.64 · 3 independent evidence families

Multiple Sclerosis, Relapsing-RemittingModerately supported
0.69
agreement 0.530.84
Clinical100%Literature0%

Open Targets aggregate 0.56 · 2 independent evidence families

PsoriasisModerately supported
0.59
agreement 0.440.75
Clinical94%Literature7%

Open Targets aggregate 0.48 · 2 independent evidence families

Immune System DiseasesModerately supported
0.57
agreement 0.420.73
Clinical100%Literature0%

Open Targets aggregate 0.46 · 2 independent evidence families

Adenocarcinoma of LungModerately supported
0.56
agreement 0.400.72
Somatic mutation85%Literature15%

Open Targets aggregate 0.61 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Multiple Sclerosis0.64
Adenocarcinoma of Lung0.61
Multiple Sclerosis, Relapsing-Remitting0.56
Carcinoma, Non-Small-Cell Lung0.55
Squamous cell lung carcinoma0.51
Psoriasis0.48
Carcinoma, Hepatocellular0.47
Immune System Diseases0.46
Neurodegenerative Diseases0.44
Lung carcinoma0.40

Drug development

4 compounds recorded · 3 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (4)
DIMETHYL FUMARATEApproval
DIROXIMEL FUMARATEApproval
MONOMETHYL FUMARATEApproval
BARDOXOLONE METHYLPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (9)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

WITHDRAWN · via dimethyl fumarate · NCT02675413

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2024-04-22

    Approval: Dimethyl fumarate Accord (EMA)

    ema · regulatory · ema · via dimethyl fumarate

  2. Regulatory approval2024-04-22

    Approval: Dimethyl fumarate Mylan (EMA)

    ema · regulatory · ema · via dimethyl fumarate

  3. Regulatory approval2024-04-22

    Approval: Dimethyl fumarate Neuraxpharm (EMA)

    ema · regulatory · ema · via dimethyl fumarate

  4. Withdrawn from market2023-12-13

    Market withdrawal: Dimethyl fumarate Accord (EMA)

    ema · market · ema · via dimethyl fumarate

  5. Withdrawn from market2023-12-13

    Market withdrawal: Dimethyl fumarate Mylan (EMA)

    ema · market · ema · via dimethyl fumarate

  6. Withdrawn from market2023-12-13

    Market withdrawal: Dimethyl fumarate Neuraxpharm (EMA)

    ema · market · ema · via dimethyl fumarate

  7. Withdrawn from market2023-12-13

    Market withdrawal: Dimethyl fumarate Polpharma (EMA)

    ema · market · ema · via dimethyl fumarate

  8. Safety communication2021-01-07

    Drug Safety Update: Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia

    mhra · safety · mhra · via dimethyl fumarate

  9. New publication2020-10-02
    SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.

    Nature communications · 2020 · 351 citations · Europe PMC · via dimethyl fumarate

  10. New publication2020-03-04
    Targeting immunometabolism as an anti-inflammatory strategy.

    Cell research · 2020 · 400 citations · Europe PMC · via dimethyl fumarate

  11. Safety communication2016-04-18

    Drug Safety Update: Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy

    mhra · safety · mhra · via dimethyl fumarate

  12. Safety communication2015-03-30

    Drug Safety Update: Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia

    mhra · safety · mhra · via dimethyl fumarate

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

10 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Zhang J · Oxidative medicine and cellular longevity · 2016

Robledinos-Antón N · Oxidative medicine and cellular longevity · 2019

Yu C · Oxidative medicine and cellular longevity · 2021

Recent

Europe PMC papers linked directly to this protein.